Search
for
Sort by
Research 331–360 of 1000+
- Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
- Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review
- Androgenetic alopecia: An update
- Review of efficacy of baricitinib in the treatment of alopecia areata
- DataSheet1_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
- CURRENT UNDERSTANDING OF VITILIGO: A COMPREHENSIVE LITERATURE REVIEW
- The Economic Burden of Alopecia Areata: Evidence from a Survey in Norway and Sweden
- ALOPECIA AREATA: ASPECTOS FISIOLÓGICOS E AVANÇOS TERAPÊUTICOS – UMA REVISÃO DE LITERATURA
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Topical metformin as a novel therapy for alopecia areata due to its immunologic effects
- Baricitinib for the Treatment of Alopecia Areata
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Emerging treatments in alopecia
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Evolving treatment paradigms in dermatology: Insights from emerging and repurposed therapies
- Deuruxolitinib for Alopecia Areata.
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- Acral Vitiligo: A Comprehensive Review of Clinical Features, Pathogenesis, and Novel Therapeutic Advances
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience